{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:49:47Z","timestamp":1792082987841,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12185-026-04219-w","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:54:05Z","timestamp":1778565245000},"page":"413-421","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["T-cell fitness, metabolic tumor volume, and serum LDH levels are associated with response to axicabtagene ciloleucel"],"prefix":"10.1007","volume":"124","author":[{"given":"Risa","family":"Nishiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hiratsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Miyagi Maeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiteru","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Aruga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiaki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Iwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Munakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Makita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"issue":"6","key":"4219_CR1","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/cas.13239","volume":"108","author":"S Makita","year":"2017","unstructured":"Makita S, Yoshimura K, Tobinai K. Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Cancer Sci. 2017;108(6):1109\u201318.","journal-title":"Cancer Sci"},{"key":"4219_CR2","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212567","volume":"8","author":"S Makita","year":"2019","unstructured":"Makita S, Imaizumi K, Kurosawa S, Tobinai K. Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges. Drugs Context. 2019;8:212567.","journal-title":"Drugs Context"},{"issue":"26","key":"4219_CR3","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"1","key":"4219_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20(1):31\u201342.","journal-title":"Lancet Oncol"},{"issue":"19","key":"4219_CR5","first-page":"2307","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141(19):2307\u201315.","journal-title":"Blood"},{"issue":"27","key":"4219_CR6","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: Results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2020;38(27):3119\u201328.","journal-title":"J Clin Oncol"},{"issue":"27","key":"4219_CR7","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1200\/JCO.19.02103","volume":"38","author":"CA Jacobson","year":"2020","unstructured":"Jacobson CA, Hunter BD, Redd R, et al. Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity. J Clin Oncol. 2020;38(27):3095\u2013106.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4219_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10147-021-02033-4","volume":"27","author":"K Kato","year":"2022","unstructured":"Kato K, Makita S, Goto H, et al. Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma. Int J Clin Oncol. 2022;27(1):213\u201323.","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"4219_CR9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s12185-022-03494-7","volume":"117","author":"K Kato","year":"2023","unstructured":"Kato K, Fujii N, Makita S, et al. A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis. Int J Hematol. 2023;117(3):409\u201320.","journal-title":"Int J Hematol"},{"issue":"7","key":"4219_CR10","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640\u201354.","journal-title":"N Engl J Med"},{"issue":"2","key":"4219_CR11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin JR, Oluwole OO, Kersten MJ, et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023;389(2):148\u201357.","journal-title":"N Engl J Med"},{"issue":"3","key":"4219_CR12","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/bjh.17673","volume":"195","author":"MS Topp","year":"2021","unstructured":"Topp MS, van Meerten T, Houot R, et al. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021;195(3):388\u201398.","journal-title":"Br J Haematol"},{"issue":"4","key":"4219_CR13","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bjh.17527","volume":"194","author":"OO Oluwole","year":"2021","unstructured":"Oluwole OO, Bouabdallah K, Mu\u00f1oz J, et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021;194(4):690\u2013700.","journal-title":"Br J Haematol"},{"issue":"3","key":"4219_CR14","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41409-023-02169-z","volume":"59","author":"OO Oluwole","year":"2024","unstructured":"Oluwole OO, Forcade E, Mu\u00f1oz J, et al. Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids. Bone Marrow Transplant. 2024;59(3):366\u201372.","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"4219_CR15","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.jtct.2024.08.018","volume":"30","author":"FL Locke","year":"2024","unstructured":"Locke FL, Neelapu SS, Bartlett NL, et al. Tocilizumab prophylaxis following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Transplant Cell Ther. 2024;30(11):1065\u201379.","journal-title":"Transplant Cell Ther"},{"key":"4219_CR16","first-page":"291","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2017","unstructured":"Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 291\u2013317.","edition":"Revised 4th ed"},{"issue":"4","key":"4219_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4219_CR18","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","volume":"41","author":"M Meignan","year":"2014","unstructured":"Meignan M, Sasanelli M, Casasnovas RO, et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging. 2014;41:1113\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"4219_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"4219_CR20","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","volume":"9","author":"RK Das","year":"2019","unstructured":"Das RK, Vernau L, Grupp SA, et al. Na\u00efve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers. Cancer Discov. 2019;9(4):492\u20139.","journal-title":"Cancer Discov"},{"issue":"4","key":"4219_CR21","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","volume":"28","author":"SS Neelapu","year":"2022","unstructured":"Neelapu SS, Dickinson M, Munoz J, et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022;28(4):735\u201342.","journal-title":"Nat Med"},{"issue":"20","key":"4219_CR22","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1182\/blood.2024027347","volume":"145","author":"JC Chavez","year":"2025","unstructured":"Chavez JC, Dickinson M, Munoz J, et al. Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study. Blood. 2025;145(20):2303\u201311.","journal-title":"Blood"},{"issue":"Suppl","key":"4219_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000975996.32786.92","volume":"7","author":"J Westin","year":"2023","unstructured":"Westin J, Jacobson C, Chavez JC, et al. ZUMA-23: a global, Phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma. Hemasphere. 2023;7(Suppl):e3278692.","journal-title":"Hemasphere"},{"issue":"26","key":"4219_CR24","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1182\/blood.2023023447","volume":"143","author":"FL Locke","year":"2024","unstructured":"Locke FL, Siddiqi T, Jacobson CA, et al. Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity. Blood. 2024;143(26):2722\u201334.","journal-title":"Blood"},{"issue":"7","key":"4219_CR25","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","volume":"29","author":"JH Park","year":"2023","unstructured":"Park JH, Nath K, Devlin SM, et al. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med. 2023;29(7):1710\u20137.","journal-title":"Nat Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04219-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04219-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04219-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:56:56Z","timestamp":1788184616000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04219-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4219"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04219-w","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.M. reports receiving research funding from AbbVie GK. S.F. reports receiving research funding from AbbVie GK, Chugai Pharmaceutical Co., Ltd., LOXO Oncology, Inc., and Tanabe Pharma Corporation, and BeOne Inc. W.M. reports receiving research funding from Chugai Pharmaceutical Co., Ltd., Genmab A\/S, Nihon Shinyaku Co., Ltd., and Ono Pharmaceutical Co., Ltd.; and honoraria from Chugai Pharmaceutical Co., Ltd. SM reports receiving honoraria from AbbVie AstraZeneca K.K., Bristol Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Genmab A\/S, and Gilead Sciences, Inc. K.I. reports receiving consultancy fees from AbbVie Inc., AstraZeneca K.K., BeOne Medicines Ltd., Bristol Myers Squibb K.K., Carna Biosciences, Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Genmab A\/S, Gilead Sciences, Inc.\/Kite Pharma, Incyte Biosciences Japan GK, Janssen Pharmaceutical K.K., Kyowa Kirin Co., Ltd., LOXO Oncology, Inc., Tanabe Pharma Corporation, MSD K.K., Nihon Shinyaku Co., Ltd., Novartis Pharma K.K.,Otsuka Pharmaceutical Co., Ltd., Symbio Pharmaceuticals Limited, Regeneron Pharmaceuticals, Inc., and Zenyaku Kogyo Co., Ltd. and research funding from AbbVie Inc., AstraZeneca K.K., Bayer Yakuhin, Ltd., BeOne Medicines Ltd., Bristol Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Genmab A\/S, Gilead Sciences, Inc.\/Kite Pharma, Incyte Biosciences Japan GK, Janssen Pharmaceutical K.K., Kyowa Kirin Co., Ltd., LOXO Oncology, Inc., MSD K.K., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Regeneron Pharmaceuticals, Inc., and Yakult Honsha Co., Ltd. and honoraria from AbbVie Inc., AstraZeneca K.K., BeOne Medicines Ltd., Bristol Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Genmab A\/S, Kyowa Kirin Co., Ltd., MSD K.K., Nihon Shinyaku Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Symbio Pharmaceuticals Limited, and Takeda Pharmaceutical Co., Ltd. The other authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}